Evidence map›Paper›PMID 33128602›Full record

ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2021

Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.

Simone Minasi, Caterina Baldi, Francesca Gianno, Manila Antonelli, Anna Maria Buccoliero, Torsten Pietsch, Maura Massimino, Francesca Romana Buttarelli

Open access · hybridAbstract read
In one paragraph

Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Simone Minasi *Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-8872-6409
Caterina Baldi *Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.ORCID 0000-0001-6831-6229
Francesca GiannoDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-6223-9952
Manila AntonelliDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-9535-931X
Anna Maria BuccolieroPathology Unit, Meyer Children's University Hospital, I-50139, Florence, Italy.ORCID 0000-0002-7113-8387
Torsten PietschInstitute of Neuropathology, DGNN Brain Tumour Reference Centre, University of Bonn Medical Centre, Bonn, Germany.ORCID 0000-0002-9252-8923
Maura MassiminoPaediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0002-5506-2001
Francesca Romana ButtarelliDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy. francesca.buttarelli@uniroma1.it.ORCID 0000-0001-5892-1281
Sapienza University of Rome · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITMeyer Children's Hospital · ITUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe maintenance of telomere length prevents cancer cell senescence and occurs via two mutually exclusive mechanisms: (a) reactivation of telomerase expression and (b) activation of alternative lengthening of telomeres (ALT). ALT is frequently related to alterations on ATRX, a chromatin-remodelling protein. Recent data have identified different molecular subgroups of paediatric high-grade glioma (pHGG) with mutations of H3F3A, TERTp and ATRX; however, differences in telomere length among these molecular subgroups were not thoroughly examined.

methodsWe investigated which genetic alterations trigger the ALT mechanism in 52 IDH-wildtype, 1p/19q-wildtype pHGG. Samples were analysed for telomere length using Tel-FISH. ATRX nuclear loss of expression was assessed by IHC, H3F3A and TERTp mutations by DNA sequencing, and TERTp methylation by MS-PCR.

resultsMutant H3.3 was found in 21 cases (40.3%): 19.2% with K27M mutation and 21.1% with G34R mutation. All H3.3G34R-mutated cases showed the ALT phenotype (100%); on the opposite, only 40% of the H3.3K27M-mutated showed ALT activation. ATRX nuclear loss was seen in 16 cases (30.7%), associated sometimes with the G34R mutation, and never with the K27M mutation. ATRX nuclear loss was always related to telomere elongation. TERTp C250T mutations were rare (5.4%) and were not associated with high intensity Tel-FISH signals, as TERTp hyper-methylation detected in 21% of the cases. H3.3/ATRX/TERTp-wildtype pHGG revealed all basal levels of telomere length.

conclusionOur results show a strong association between H3.3 mutations and ALT, and highlight the different telomeric profiles in histone-defined subgroups: H3.3-G34R mutants always trigger ALT to maintain telomere length, irrespective of ATRX status, whereas only some H3.3-K27M tumours activate ALT. These findings suggest that acquiring the gly34 mutation on H3.3 might suffice to trigger the ALT mechanism.

Indexed as

Brain NeoplasmsGliomaChildHumansMutationTelomereTelomere HomeostasisX-linked Nuclear ProteinX-linked Nuclear ProteinAlternative lengthening of telomeresH3.3Paediatric high-grade gliomaspHGGTelomeres

Identifiers

PMID33128602
PMCPMC7875853
OpenAlexW3097650579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.